Fujian Cancer Hospital
Clinical trials sponsored by Fujian Cancer Hospital, explained in plain language.
-
Cancer trial questions need for full radiation dose
Disease control Not yet recruitingThis study is testing whether doctors can safely skip part of the radiation treatment for certain nasopharyngeal cancer patients. Researchers want to see if omitting radiation to a specific neck area (Level Va) in patients without certain risk features works as well as the standa…
Phase: PHASE3 • Sponsor: Fujian Cancer Hospital • Aim: Disease control
Last updated Apr 03, 2026 14:41 UTC
-
New drug combo aims to control tough head & neck cancers
Disease control Not yet recruitingThis study is testing whether a combination of three drugs (sintilimab, nimotuzumab, and chemotherapy) followed by radiation can better control locally advanced head and neck cancer. It will involve about 23 adults who have not had prior treatment for this cancer. The main goal i…
Phase: PHASE2 • Sponsor: Fujian Cancer Hospital • Aim: Disease control
Last updated Apr 02, 2026 14:58 UTC
-
Timing is everything: new trial aims to Fine-Tune cancer treatment
Disease control Not yet recruitingThis study is for people with advanced nasopharyngeal cancer. It aims to find the best day to add an immunotherapy drug (toripalimab) to standard chemotherapy before radiation. Researchers will compare giving the drug on Day 1, Day 5, or Day 9 of the chemo cycle to see which timi…
Phase: PHASE2 • Sponsor: Fujian Cancer Hospital • Aim: Disease control
Last updated Mar 31, 2026 12:12 UTC
-
New hope for patients whose nasopharyngeal cancer returns
Disease control Not yet recruitingThis study is testing a new combination treatment for people whose nasopharyngeal cancer has returned in the original area after initial treatment. It will enroll 25 patients to receive an initial phase of two drugs (MRG003 and Tislelizumab) followed by a year of maintenance ther…
Phase: PHASE2 • Sponsor: Fujian Cancer Hospital • Aim: Disease control
Last updated Mar 30, 2026 14:35 UTC
-
New drug aims to tame severe side effects, let cancer patients resume lifesaving treatment
Disease control Not yet recruitingThis study is testing a drug called Ivarmacitinib for people with advanced solid tumors who had to stop a promising type of cancer treatment (immunotherapy) because of severe side effects. The goal is to see if Ivarmacitinib can help control these side effects so that patients mi…
Phase: PHASE2 • Sponsor: Fujian Cancer Hospital • Aim: Disease control
Last updated Mar 30, 2026 14:32 UTC
-
Gut bacteria boost for liver cancer treatment?
Disease control Not yet recruitingThis study is testing if taking a specific probiotic (Lactobacillus reuteri) before surgery, along with standard immunotherapy, helps patients with liver cancer. It aims to see if this combination helps the liver recover better after surgery and improves long-term survival. Resea…
Phase: NA • Sponsor: Fujian Cancer Hospital • Aim: Disease control
Last updated Mar 27, 2026 12:40 UTC
-
Cancer treatment crossroads: which path works better when first drugs fail?
Disease control Not yet recruitingThis study aims to find out which treatment approach works better for patients with advanced nasopharyngeal cancer when their initial chemotherapy doesn't shrink the tumor enough. Researchers will observe 223 patients who receive either additional chemotherapy followed by radiati…
Sponsor: Fujian Cancer Hospital • Aim: Disease control
Last updated Mar 27, 2026 12:37 UTC
-
New hope for rare, Fast-Spreading esophageal cancer?
Disease control Not yet recruitingThis study is testing if adding an immunotherapy drug (serplulimab) to standard chemotherapy before surgery can help people with a rare and aggressive type of esophageal cancer called small cell carcinoma. The goal is to see if this combination can shrink or even eliminate the tu…
Phase: PHASE2 • Sponsor: Fujian Cancer Hospital • Aim: Disease control
Last updated Mar 25, 2026 14:08 UTC
-
New Triple-Threat attack on advanced kidney cancer being tested
Disease control Not yet recruitingThis study is testing a three-part treatment for advanced kidney cancer that has spread. It combines a precise, high-dose radiation treatment (SBRT) with two drugs: one that blocks tumor blood supply and one that boosts the immune system. The goal is to see how well this combinat…
Phase: PHASE2 • Sponsor: Fujian Cancer Hospital • Aim: Disease control
Last updated Mar 20, 2026 14:48 UTC
-
New drug aims to stop dangerous blood side effect in breast cancer patients
Prevention Not yet recruitingThis study is testing whether a drug called hetrombopag can prevent or reduce severe drops in platelet counts (thrombocytopenia) caused by a specific type of breast cancer treatment known as ADC drugs. It will involve 72 breast cancer patients who are either starting this treatme…
Phase: PHASE2 • Sponsor: Fujian Cancer Hospital • Aim: Prevention
Last updated Apr 03, 2026 14:41 UTC
-
New drug tested to shield cancer patients from Chemotherapy's Blood-Thinning danger
Prevention Not yet recruitingThis study is testing whether a drug called hetrombopag can prevent a serious side effect of chemotherapy for nasopharyngeal (nose and throat) cancer. The side effect, called thrombocytopenia, is when platelet counts drop too low, raising the risk of dangerous bleeding. The study…
Phase: PHASE2 • Sponsor: Fujian Cancer Hospital • Aim: Prevention
Last updated Apr 02, 2026 14:56 UTC
-
New cream trial aims to soothe painful side effect of cervical cancer treatment
Symptom relief Not yet recruitingThis study is testing whether a cream called triethanolamine can prevent or reduce vaginal inflammation (radiation vaginitis) caused by radiotherapy for cervical cancer. Researchers will compare the cream plus standard care against standard care alone in about 238 patients. The m…
Phase: PHASE4 • Sponsor: Fujian Cancer Hospital • Aim: Symptom relief
Last updated Apr 01, 2026 14:42 UTC